Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05615467 · ClinicalTrials.gov registry record · Phase 1
A Study of Effect of LY3556050 on Metformin in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05615467 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT05615467, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate how much Metformin gets into the bloodstream and how long the body takes to get rid of it when it is administered orally in combination with LY3556050 in healthy participants. Iohexol will be administered to evaluate kidney function. Each enrolled participant will remain in the study for up to 7 weeks including the screening period.
Interventions
- DRUG Metformin
- DRUG Iohexol
- DRUG LY3556050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2022-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05615467
The ClinicalTrials.gov registry entry for NCT05615467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT05615467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05615467 about?
NCT05615467 is a clinical study titled "A Study of Effect of LY3556050 on Metformin in Healthy Participants". The main purpose of this study is to evaluate how much Metformin gets into the bloodstream and how long the body takes to get rid of it when it is administered orally in combination with LY3556050 in healthy participants. Iohexol will be administered to evaluate kidney function. Each enrolled partic...
What is the current status of trial NCT05615467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-11-15. Estimated completion is 2022-12-27.
What interventions are being tested in trial NCT05615467?
The interventions under investigation include: Metformin (DRUG), Iohexol (DRUG), LY3556050 (DRUG).
Who is sponsoring clinical trial NCT05615467?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.